Live Feeds

Source map — Merck licenses a KRAS G12D inhibitor for $400M upfront

Every domain this feed has drawn corroborated signal from. We store facts and short excerpts and link back to originals — never republished article bodies.

SourceTypeTrust
Reuters news 60%
Fierce Biotech news 60%
Business Wire news 60%
BioSpace news 60%
endpoints.news news 60%
www.ad-hoc-news.de news 50%
updates.biomednexus.com news 50%
www.ddw-online.com news 50%
iswtcommunity.substack.com news 50%
www.p05.org news 50%
biotechmorning.com news 50%
squawknews.com news 50%
jimmyresearch.com news 50%
www.biorichinc.com news 50%
www.talk.bio news 50%
cdmohub.ai news 50%
dealforma.com news 50%
finance.yahoo.com news 50%
oncodaily.com news 50%
biobuzz.io news 50%
en.wikipedia.org news 50%
medcitynews.com news 50%
guavy.com news 50%
www.fiercebiotech.com news 50%
allsci.com news 50%
www.pharmexec.com news 50%
jobs.merck.com news 50%
www.merck.com news 50%
pharmaphorum.com news 50%
www.biobucks.co news 50%